JAMA : the journal of the American Medical Association
-
Surrogate markers are increasingly used as primary end points in clinical trials supporting drug approvals. ⋯ Most surrogate markers used as primary end points in clinical trials to support FDA approval of drugs treating nononcologic chronic diseases lacked high-strength evidence of associations with clinical outcomes from published meta-analyses.